Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 304

1.

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia.

Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr.

J Clin Oncol. 2001 Sep 15;19(18):3852-60.

PMID:
11559723
2.

Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: a bridge to transplantation.

Leoni F, Gianfaldoni G, Annunziata M, Fanci R, Ciolli S, Nozzoli C, Ferrara F.

Haematologica. 2002 May;87(5):485-9.

3.

Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.

Thirugnanam R, George B, Chendamarai E, Lakshmi KM, Balasubramanian P, Viswabandya A, Srivastava A, Chandy M, Mathews V.

Biol Blood Marrow Transplant. 2009 Nov;15(11):1479-84. doi: 10.1016/j.bbmt.2009.07.010. Epub 2009 Sep 1.

4.
5.

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen Z, Hu J, Shen ZX, Chen SJ.

Blood. 1999 Nov 15;94(10):3315-24.

6.

Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.

Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, Shinjo K, Takeshita A, Ohno R, Ohnishi K.

Int J Hematol. 2005 Oct;82(3):224-9.

PMID:
16207595
7.

Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy.

Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, Rostami S, Jahani M, Hosseini R, Mossavi A, Baybordi E, Khodabadeh A, Iravani M, Bahar B, Mortazavi Y, Totonchi M, Aghdami N.

Ann Oncol. 2006 Jan;17(1):131-4. Epub 2005 Oct 14.

8.

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience.

Lazo G, Kantarjian H, Estey E, Thomas D, O'Brien S, Cortes J.

Cancer. 2003 May 1;97(9):2218-24.

9.

Effect of arsenic trioxide on QT interval in patients with advanced malignancies.

Barbey JT, Pezzullo JC, Soignet SL.

J Clin Oncol. 2003 Oct 1;21(19):3609-15.

PMID:
14512391
10.

Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.

Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M.

J Clin Oncol. 2011 Jul 10;29(20):2753-7. doi: 10.1200/JCO.2010.32.2107. Epub 2011 Jun 6.

11.
12.

Retrospective study of arsenic trioxide for childhood acute promyelocytic leukemia in China: a single-center experience.

Wang H, Hao L, Wang X, Li J, Wu Q, Bian S.

Int J Hematol. 2010 Jun;91(5):820-5. doi: 10.1007/s12185-010-0575-z. Epub 2010 May 13.

PMID:
20461563
13.

Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.

Carmosino I, Latagliata R, Avvisati G, Breccia M, Finolezzi E, Lo Coco F, Petti MC.

Haematologica. 2004 May;89(5):615-7.

14.

Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia.

Zhou J, Zhang Y, Li J, Li X, Hou J, Zhao Y, Liu X, Han X, Hu L, Wang S, Zhao Y, Zhang Y, Fan S, Lv C, Li L, Zhu L.

Blood. 2010 Mar 4;115(9):1697-702. doi: 10.1182/blood-2009-07-230805. Epub 2009 Dec 22.

15.

Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.

Estey E, Garcia-Manero G, Ferrajoli A, Faderl S, Verstovsek S, Jones D, Kantarjian H.

Blood. 2006 May 1;107(9):3469-73. Epub 2005 Dec 22.

16.
17.

All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia.

Shen ZX, Shi ZZ, Fang J, Gu BW, Li JM, Zhu YM, Shi JY, Zheng PZ, Yan H, Liu YF, Chen Y, Shen Y, Wu W, Tang W, Waxman S, De Thé H, Wang ZY, Chen SJ, Chen Z.

Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35. Epub 2004 Mar 24.

18.

Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia.

Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, Faderl SH, Laddie NM, Garcia-Manero G, Cortes JE.

Cancer. 2007 Apr 1;109(7):1355-9.

19.

Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience.

Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A.

Am J Hematol. 2002 Aug;70(4):292-9.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk